Adze Biotechnology

Adze Biotechnology develops a pipeline of oncolytic immunotherapies built on a proprietary oncolytic viral backbone. The backbone enables systemic delivery of immunotherapies and checkpoint inhibitors that self-amplify, or conditionally replicate, locally in tumors, including solid tumors previously inaccessible to these types of therapies.

Its differentiation rests on delivery: candidates carry checkpoint-inhibitor and immune-modulating payloads directly into tumors, with retargeted sub-platforms designed to enhance anti-PD-1 therapy performance. The company targets patients with solid tumors and builds strategic partnerships with major pharmaceutical companies to convert its platform advantage into multiple drug candidates.